Nora Irene Hipp

Associate

Dr. rer. nat., M.Sc., B.Sc.

Dr. Nora Irene Hipp has been active in the field of intellectual property since 2015 and is authorized to represent clients before the German Patent and Trademark Office (GPTO), the German Federal Patent Court (GFPC), the German Federal Court of Justice (FSC; in appeals from the GFPC) as well as the European Union Intellectual Property Office (EUIPO). Since 2018, she complements df mp's expertise in the Biotechnology and Pharmaceuticals Divisions.

+ 49 89 210 296 0
nora.hipp@df-mp.com

Nora Irene Hipp

Associate

Dr. rer. nat., M.Sc., B.Sc.

Dr. Nora Irene Hipp has been active in the field of intellectual property since 2015 and is authorized to represent clients before the German Patent and Trademark Office (GPTO), the German Federal Patent Court (GFPC), the German Federal Court of Justice (FSC; in appeals from the GFPC) as well as the European Union Intellectual Property Office (EUIPO). Since 2018, she complements df mp's expertise in the Biotechnology and Pharmaceuticals Divisions.

+ 49 89 210 296 0
nora.hipp@df-mp.com

practice areas.

Dr. Hipp has in-depth technical expertise inter alia in the fields of molecular biology, biochemistry, cell biology, immunology and epigenetics, particularly in relation to tumor diseases. As a member of df mp‘s Biotechnology and Pharmaceuticals Divisions, her activities focus on drafting and prosecuting patent applications, opposition proceedings and patent litigation.

admissions.

  • German Patent Attorney
  • European Trademark Attorney
  • European Design Attorney

references and activities.

  • Author and Co-Author of scientific publications in international journals in the field of tumor biology
  • Various presentations in the field of tumor biology

curriculum vitae.

Since October 2018
Since October 2018

Patent Att­or­ney at df-mp

2015-2018
2015-2018

Patent Att­or­ney can­di­da­te in the law firm König — Szyn­ka — Til­mann — von Renes­se, trai­nee at the Ger­man Patent and Trade­mark Office and the Ger­man Fede­ral Patent Court

2009-2014
2009-2014

Doc­to­ra­te and sci­en­ti­fic employee at Ulm Uni­ver­si­ty, Insti­tu­te of Phy­sio­lo­gi­cal Che­mis­try, Ph.D. the­sis on mecha­nisms of MYC-indu­­ced tumo­rig­e­ne­sis in tumor enti­ties of all three germ lay­ers

2003-2008
2003-2008

Stu­dies in Mole­cu­lar Medi­ci­ne at Ulm Uni­ver­si­ty Bache­lor The­sis, Depart­ment of Expe­ri­men­tal Neu­ro­lo­gy in the field of neu­ro­re­ge­ne­ra­ti­on of the CNS Mas­ter The­sis, Depart­ment of Pedia­trics and Ado­le­s­cent Medi­ci­ne at the Uni­ver­si­ty Medi­cal Cent­re Ulm deal­ing with pathome­cha­nisms of neu­ro­blasto­ma

publications.

  • Hipp et al., "MYCN and survivincooperatively contribute to malignant transformation of fibroblasts."Carcinogenesis (2014); 35(2):479-88.
  • Sunami et al., "Hepatic activation of IKK/NFκB signaling induces liver fibrosis via macrophage-mediated chronic inflammation." Hepatology (2012); 56(3):1117-28.
  • Wahl et al., "Ewing's sarcoma cells with CD57-associated increase of tumorigenicity and with neural crest-like differentiation capacity."International Journal of Cancer (2010); 127(6):1295-307.